Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as well as taking on the top role and shaking up the board. The Dundee and New Jersey-based biotech ended September with just $3 million in the bank and the expectation that these funds would run out before year-end. Source: Fierce Biotech 3/1/2025